Your browser doesn't support javascript.
loading
Lactate: an alternative pathway for the immunosuppressive properties of mesenchymal stem/stromal cells.
Pradenas, Carolina; Luque-Campos, Noymar; Oyarce, Karina; Contreras-Lopez, Rafael; Bustamante-Barrientos, Felipe A; Bustos, Andrés; Galvez-Jiron, Felipe; Araya, María Jesús; Asencio, Catalina; Lagos, Raúl; Herrera-Luna, Yeimi; Abba Moussa, Daouda; Hill, Charlotte Nicole; Lara-Barba, Eliana; Altamirano, Claudia; Ortloff, Alexander; Hidalgo-Fadic, Yessia; Vega-Letter, Ana María; García-Robles, María de Los Ángeles; Djouad, Farida; Luz-Crawford, Patricia; Elizondo-Vega, Roberto.
Afiliación
  • Pradenas C; Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
  • Luque-Campos N; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Oyarce K; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Contreras-Lopez R; IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile.
  • Bustamante-Barrientos FA; Facultad de Medicina y Ciencia, Universidad San Sebastián, Concepción, Chile.
  • Bustos A; IRMB, University of Montpellier, INSERM, 34295, Montpellier, France.
  • Galvez-Jiron F; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Araya MJ; IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile.
  • Asencio C; Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
  • Lagos R; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Herrera-Luna Y; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Abba Moussa D; IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile.
  • Hill CN; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Lara-Barba E; IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile.
  • Altamirano C; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Ortloff A; Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
  • Hidalgo-Fadic Y; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Vega-Letter AM; IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile.
  • García-Robles MLÁ; IRMB, University of Montpellier, INSERM, 34295, Montpellier, France.
  • Djouad F; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
  • Luz-Crawford P; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Elizondo-Vega R; Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
Stem Cell Res Ther ; 14(1): 335, 2023 11 19.
Article en En | MEDLINE | ID: mdl-37981698
ABSTRACT

BACKGROUND:

The metabolic reprogramming of mesenchymal stem/stromal cells (MSC) favoring glycolysis has recently emerged as a new approach to improve their immunotherapeutic abilities. This strategy is associated with greater lactate release, and interestingly, recent studies have proposed lactate as a functional suppressive molecule, changing the old paradigm of lactate as a waste product. Therefore, we evaluated the role of lactate as an alternative mediator of MSC immunosuppressive properties and its contribution to the enhanced immunoregulatory activity of glycolytic MSCs. MATERIALS AND

METHODS:

Murine CD4+ T cells from C57BL/6 male mice were differentiated into proinflammatory Th1 or Th17 cells and cultured with either L-lactate, MSCs pretreated or not with the glycolytic inductor, oligomycin, and MSCs pretreated or not with a chemical inhibitor of lactate dehydrogenase A (LDHA), galloflavin or LDH siRNA to prevent lactate production. Additionally, we validated our results using human umbilical cord-derived MSCs (UC-MSCs) in a murine model of delayed type 1 hypersensitivity (DTH).

RESULTS:

Our results showed that 50 mM of exogenous L-lactate inhibited the proliferation rate and phenotype of CD4+ T cell-derived Th1 or Th17 by 40% and 60%, respectively. Moreover, the suppressive activity of both glycolytic and basal MSCs was impaired when LDH activity was reduced. Likewise, in the DTH inflammation model, lactate production was required for MSC anti-inflammatory activity. This lactate dependent-immunosuppressive mechanism was confirmed in UC-MSCs through the inhibition of LDH, which significantly decreased their capacity to control proliferation of activated CD4+ and CD8+ human T cells by 30%.

CONCLUSION:

These findings identify a new MSC immunosuppressive pathway that is independent of the classical suppressive mechanism and demonstrated that the enhanced suppressive and therapeutic abilities of glycolytic MSCs depend at least in part on lactate production.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácido Láctico / Células Madre Mesenquimatosas Límite: Animals / Humans / Male Idioma: En Revista: Stem Cell Res Ther Año: 2023 Tipo del documento: Article País de afiliación: Chile

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ácido Láctico / Células Madre Mesenquimatosas Límite: Animals / Humans / Male Idioma: En Revista: Stem Cell Res Ther Año: 2023 Tipo del documento: Article País de afiliación: Chile